Slide Deck

Executive Summary

Johnson & Johnson (JNJ) operates as a profoundly transformed entity in 2026, having shed its legacy consumer health division (Kenvue) to become a pure-play, diversified healthcare conglomerate focused strictly on Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The fundamental investment debate surrounding the company centers on a critical tension: the historical durability of its cash flows and defensive market positioning versus a daunting confluence of structural headwinds. These headwinds include a massive pharmaceutical patent cliff headlined by the loss of exclusivity for the immunology blockbuster Stelara, intense pricing pressures stemming from the U.S. Inflation Reduction Act (IRA), an underperforming orthopedics device segment, and the persistent, unquantifiable overhang of the sprawling talcum powder litigation.

This report evaluates Johnson & Johnson through a rigorous framework of competitive advantage, organic growth sustainability, and capital allocation efficiency. The analysis dissects the underlying unit economics of the business, separating management’s optimistic forward guidance from the empirical realities reflected in return on invested capital (ROIC), operating margins, and market share dynamics. The ultimate objective is to determine whether Johnson & Johnson possesses the requisite growth catalysts and capital discipline to generate excess returns at current valuations, or if the enterprise is a maturing, ex-growth incumbent trading primarily on its legacy reputation as a dividend aristocrat. The baseline thesis requires that a competitively advantaged business must translate its market position into a return on capital that consistently exceeds its weighted average cost of capital (WACC), while reinvesting at high rates to compound intrinsic value.

1. Competitive Advantage Assessment

A sustainable competitive advantage, or economic moat, must invariably manifest in superior, long-term financial performance. For a diversified healthcare conglomerate of Johnson & Johnson’s magnitude, this is measured through pricing power, high switching costs, and the ability to generate a Return on Invested Capital (ROIC) that consistently exceeds the WACC. Without a demonstrable quantitative spread between ROIC and WACC, any qualitative claims of a “moat” are effectively void.

Financial Proof of the Economic Moat

Johnson & Johnson operates with a WACC estimated between 7.08% and 7.18%.¹ Against this cost of capital, the enterprise has historically generated robust returns, confirming the presence of an economic moat, though the trajectory reveals underlying pressures that require continuous capital deployment to defend. The company’s ROIC for the trailing twelve months (TTM) ended in late 2025 stood at approximately 15.96%, having experienced fluctuations between 13.52% and 22.14% over the preceding ten-year period.² This positive spread of roughly 700 to 900 basis points above the cost of capital confirms that the company effectively utilizes its capital to generate excess returns.

However, a deeper examination of the return on equity (ROE) and margin profile indicates a business requiring continuous, aggressive reinvestment to maintain its positioning. ROE for the trailing twelve months ending September 2025 was recorded at an impressive 31.69%, driven significantly by the high-margin Innovative Medicine segment and the mathematical effects of stock repurchases shrinking the equity base.³

The consolidated gross margin profile serves as the primary indicator of pricing power. Over the past decade, Johnson & Johnson has maintained gross margins in a remarkably tight band between 64.06% and 70.28%, with the 2025 full-year gross margin registering at 67.88%.⁴ This stability is extraordinary given the inflationary environment, wage pressures, and supply chain disruptions characterizing the post-2020 macroeconomic landscape. The ability to defend a ~68% gross margin profile provides empirical evidence that the company’s therapeutic and surgical products command premium pricing and are relatively insulated from commoditization, barring the entry of direct generic or biosimilar competition.⁴ Operating margins, which hovered around 33.5% to 35.0% by late 2025, further reflect the operating leverage inherent in the business, scaling efficiently following the divestiture of the lower-margin consumer health division.⁵

Financial Return Metric	2020	2021	2022	2023	2024	2025 (TTM/Est)
Gross Margin	65.58%	70.28%	69.25%	68.82%	69.07%	67.88% 4
Operating Margin	~24.1%	~25.5%	26.5%	25.8%	27.9%	~33.5% 6
Return on Equity (ROE)	26.35%	25.44%	25.68%	51.11%*	19.68%	31.69% 3
Return on Invested Capital (ROIC)	16.72%	20.54%	17.39%	20.17%	17.00%	15.96% 2

*Note: 2023 ROE distortion reflects the accounting impact and equity reduction from the Kenvue spin-off.²

Switching Costs and Network Effects: The MedTech Workflow Friction

The durability of Johnson & Johnson’s moat is largely predicated on high switching costs, particularly within the MedTech division. These costs are not merely financial; they are deeply embedded in clinical workflows and human capital.⁷

In the MedTech sector, specifically within electrophysiology (Biosense Webster) and cardiovascular interventions (Abiomed and Shockwave), the competitive advantage is derived from “workflow friction” and surgeon training.⁷ When a hospital network procures capital equipment—such as cardiac mapping systems, intra-aortic balloon pumps, or robotic-assisted surgery (RAS) platforms—it initiates a long-term ecosystem lock-in. Surgeons, nurses, and operating room technicians spend hundreds of hours training on specific proprietary interfaces.⁷

Switching to a competitor’s system incurs substantial non-financial and operational costs: the psychological resistance of surgeons who have developed “muscle memory” on a specific device, the temporary but costly reduction in procedural volume during the retraining phase, and the heightened risk of clinical errors during the transition.⁷ This dynamic creates a “razor and razorblade” business model where the initial capital equipment placement guarantees years of high-margin recurring revenue from single-use consumables (catheters, specialized guidewires, and robotic arms).

Johnson & Johnson is attempting to leverage this exact switching cost dynamic with the development of its OTTAVA robotic surgical system, which was recently submitted to the U.S. FDA.⁹ The strategic imperative behind OTTAVA is to bundle the robotic platform with the company’s ubiquitous Ethicon surgical instruments, attempting to disrupt the near-monopoly held by Intuitive Surgical’s da Vinci platform.¹⁰ However, this reveals the double-edged nature of switching costs. Intuitive Surgical possesses an installed base of over 9,200 systems globally and has accumulated data from over 15 million procedures.¹¹ Intuitive’s own switching costs act as a formidable barrier to entry against Johnson & Johnson. The success of OTTAVA will serve as a critical test of whether Johnson & Johnson’s vast hospital contracting leverage and GPO (Group Purchasing Organization) relationships can overcome the entrenched workflow friction protecting its rivals.¹²

The Illusion of Brand Value in Pharmaceuticals

With the spin-off of Kenvue, the legacy concept of the “Johnson & Johnson Brand”—built over a century on baby shampoo, Band-Aids, and Tylenol—is largely irrelevant to the core investment thesis. In the prescription pharmaceutical space (Innovative Medicine), brand value does not dictate market share; clinical efficacy, safety profiles, and payer formulary placement dictate market share.

In Innovative Medicine, switching costs are present but less structurally permanent than in MedTech. They exist primarily in the form of patient adherence and physician prescribing habits for chronic conditions (e.g., immunology and neuroscience). A patient stabilized on a specific biologic, such as Tremfya for plaque psoriasis, is unlikely to be switched to a competitor’s branded drug solely for marginal cost reasons, as the clinical risk of a disease flare-up outweighs the financial benefit. However, this moat evaporates instantly upon patent expiration. When a biologic faces biosimilar competition, pharmacists and Pharmacy Benefit Managers (PBMs) force substitution to interchangeable biosimilars to capture rebates and lower systemic costs.¹⁴ Therefore, the pharmaceutical moat is strictly temporal, defined precisely by the lifespan of intellectual property protection.

2. Industry Dynamics & Competitive Position

Johnson & Johnson operates in a highly polarized global healthcare environment, forced to balance the demand for rapid, capital-intensive technological innovation against aggressive, coordinated global cost-containment initiatives from governments and private payers. The company’s competitive positioning must be bifurcated between its two core segments, as they face vastly different structural dynamics.

Innovative Medicine: The Patent Cliff Vacuum

The pharmaceutical sector is defined by the perpetual, brutal cycle of innovation and patent expiration. The global pharmaceutical industry is currently facing a “$300 billion vacuum” between 2025 and 2030, a period where roughly one-sixth of the industry’s annual revenue will lose patent exclusivity, exposing major branded medicines to generic and biosimilar decimation.¹⁶

For Johnson & Johnson, the immediate crisis centers on Stelara (ustekinumab), an interleukin-12 and interleukin-23 antagonist used for autoimmune conditions like psoriasis, Crohn’s disease, and ulcerative colitis. Stelara was a commercial juggernaut, generating peak annual sales of approximately $10.9 billion in 2023.¹⁸ With the entry of multiple fully interchangeable biosimilars (manufactured by Amgen, Teva, Alvotech, and Sandoz) in early 2025, the revenue erosion was immediate.¹⁵ In 2025, Stelara sales plummeted by 41.3% to $6.08 billion, acting as a severe 1,110 basis point drag on the Innovative Medicine segment’s overall growth rate.²⁰

Despite this devastating loss of high-margin revenue, the broader Innovative Medicine segment demonstrated remarkable resilience, growing adjusted operational sales by 4.1% to $60.4 billion in 2025.⁹ This growth was engineered through sheer volume and market share gains in the oncology portfolio, proving that the company’s R&D pipeline is currently capable of replacing lost legacy revenues.

The multiple myeloma franchise is particularly dominant and represents the crown jewel of the portfolio. Darzalex (daratumumab) grew by 23.0% year-over-year to $14.35 billion in 2025, consistently achieving over $3 billion in sales per quarter.⁹ The company claims that an astonishing 80% of multiple myeloma patients receive a Johnson & Johnson therapy at some point in their treatment journey.²³ This dominance is being fortified by the rapid scaling of advanced cell therapies like Carvykti (BCMA CAR-T) and off-the-shelf bispecific antibodies (Tecvayli and Talvey), which provide a multi-pronged defense against competitors like Bristol-Myers Squibb.²³

Furthermore, the immunology division successfully executed a product transition strategy, shifting the narrative away from the Stelara decline. Tremfya (guselkumab), the designated next-generation successor targeting IL-23, recorded exceptional 2025 sales of $5.2 billion, a 40.5% increase year-over-year.²⁰ The strategic execution of shifting patients and prescribers to a newer, patent-protected asset before biosimilar devastation is fully realized is a testament to the company’s elite commercial execution capabilities.

Major JNJ Drugs Facing Patent Cliffs (2025-2030)	Therapeutic Area	Peak Sales Est. / 2024 Sales	Exclusivity Loss Window	Threat Type
Stelara (ustekinumab)	Immunology	~$10.9 Billion	2025 (US) 24	Biosimilars (Amgen, Teva, Sandoz) 19
Xarelto (rivaroxaban)	Cardiovascular	~$2.37 Billion	2025-2026 23	Small-Molecule Generic / IRA Cuts 23
Opsumit (macitentan)	Pulm. Hypertension	~$2.18 Billion	2025-2026 23	Small-Molecule Generic 23
Uptravi (selexipag)	Pulm. Hypertension	~$1.81 Billion	2026-2027 23	Small-Molecule Generic 23
Imbruvica (ibrutinib)	Oncology	~$3.0+ Billion	2027-2028 23	Small-Molecule Generic 24
Darzalex (daratumumab)	Oncology	~$14.35 Billion (2025)	~2029 23	Biosimilars 23

MedTech: A Bipolar Portfolio of Haves and Have-Nots

The MedTech segment generated $33.79 billion in 2025 sales, delivering a 5.4% operational increase, and represents roughly 36% of total enterprise revenue.⁹ The division’s competitive positioning is highly fragmented, best described as a portfolio of “haves” and “have-nots.”

The “haves” are highly concentrated in cardiovascular interventions and electrophysiology. In 2025, the Cardiovascular business grew by an exceptional 15.8% to $8.93 billion.²⁶ This growth was not entirely organic; it was catalyzed by aggressive inorganic capital deployment, specifically the mega-acquisitions of Abiomed (heart recovery via Impella pumps) and Shockwave Medical (intravascular lithotripsy for calcified arterial lesions). These assets operate in high-growth, high-margin, underpenetrated markets where Johnson & Johnson now holds undisputed category leadership, effectively creating a monopoly in the intravascular lithotripsy space where Shockwave faces no direct competitors.²⁶

Conversely, the “have-nots” are anchored by the Orthopaedics business (hips, knees, trauma, and spine). Generating $9.26 billion in 2025, Orthopaedics grew an anemic 1.1%.²⁶ The division has consistently lost market share to more nimble, technologically advanced competitors like Stryker, which has aggressively captured the orthopedic robotics space with its Mako system, generating $9.1 billion in orthopedic revenue in 2024 and growing over 8%.²⁹ Zimmer Biomet’s momentum in robotics has further marginalized Johnson & Johnson, leaving it to play catch-up in a category it once led.²⁹ Recognizing the structural drag of this legacy business, management announced in late 2025 the intention to spin off the Orthopaedics franchise into a standalone entity, DePuy Synthes, projected for mid-2027.²⁵ This portfolio optimization strategy is a tacit admission of competitive defeat. By discarding low-growth, mature assets, management aims to artificially inflate the core company’s organic growth rate and justify a higher valuation multiple.³⁰

Regulatory Headwinds and the PBM Threat

Johnson & Johnson’s competitive positioning is constantly threatened by global regulatory architecture and supply chain intermediaries.

In the United States, the Inflation Reduction Act (IRA) and the Medicare Part D redesign represent profound structural challenges. The IRA introduces direct government price negotiations for high-expenditure drugs, fundamentally undermining the industry’s historical pricing power.³¹ Johnson & Johnson has significant exposure here, with drugs like Xarelto facing negotiated Medicare prices that are over 60% lower than their 2023 list prices.²³ The redesign of Medicare Part D shifts more catastrophic liability onto the manufacturer, acting as a direct tax on top-line revenue.²⁰

Furthermore, the pharmaceutical supply chain is dominated by Pharmacy Benefit Managers (PBMs) like CVS Caremark, Express Scripts, and Optum Rx. These entities demand massive rebates to place drugs on favorable formulary tiers.³² The launch of Stelara biosimilars triggered a “price war” orchestrated by PBMs, who launched private-label biosimilars (e.g., Quallent) to maximize their own spread while driving down J&J’s market share.¹⁴ The rise of direct-to-consumer pharmacy models, such as Amazon Pharmacy offering flat-cash pricing, threatens to upend the opaque rebate model.³³ While increased transparency might theoretically benefit manufacturers by highlighting PBM markups, it injects massive volatility into J&J’s distribution channels and gross-to-net pricing assumptions.³⁵

Internationally, the MedTech division is under siege from China’s Volume-Based Procurement (VBP) program. VBP is a government-driven cost-containment mandate that forces medical device manufacturers into a race to the bottom, slashing prices drastically in exchange for guaranteed provincial volume.³⁶ Management has repeatedly cited VBP as a persistent headwind suppressing MedTech growth in the Asia-Pacific region, with no immediate relief expected in 2026.³⁷ Furthermore, geopolitical tensions have materialized in the form of expected tariff costs, which management anticipates will reach approximately $500 million in 2026, directly compressing MedTech operating margins.²⁵

3. Growth Analysis

A competitively advantaged business without growth is akin to a melting ice cube; shareholder value creation requires both a high ROIC and the ability to reinvest retained earnings at those high rates of return. A granular analysis of Johnson & Johnson’s organic growth reveals a company leveraging massive scale to generate low-to-mid single-digit expansion, heavily reliant on a few superstar assets.

Historical Growth and 2026 Guidance

Historically, Johnson & Johnson’s organic growth has tracked in the low-to-mid single digits, reflecting its massive revenue base and the law of large numbers. In 2025, the company delivered $94.2 billion in total worldwide sales, representing a 6.0% reported increase and a 4.2% adjusted operational increase (excluding the impacts of acquisitions, divestitures, and currency fluctuations).⁹

Looking forward, the company’s 2026 guidance is highly ambitious, targeting $100.0 billion to $101.0 billion in sales, representing a 6.7% reported growth rate at the midpoint.⁹ Management expects adjusted operational EPS to grow between 5.9% and 7.9%.⁹ This guidance is aggressive because it requires the company to absorb the full annualized impact of the Stelara biosimilar erosion (which already created an 1110 basis point drag in late 2025), the impending generic competition for Simponi and Opsumit, and the aforementioned $500 million MedTech tariff burden.³⁶

Growth Drivers: Pipeline Strength and MedTech Launches

The realization of the 2026 targets is wholly dependent on flawless commercial execution of recently launched products and late-stage pipeline assets.

Within Innovative Medicine, the pipeline is focused on novel mechanisms of action. The recent FDA approval of Rybrevant plus Lazcluze for EGFR-mutated non-small cell lung cancer positions the company to directly challenge AstraZeneca’s Tagrisso, establishing a new standard of care.⁹ The company is also betting heavily on nipocalimab (Imaavy), an FcRn blocker for generalized myasthenia gravis, which management believes has “pipeline-in-a-product” potential to treat multiple autoantibody-driven diseases, directly competing with argenx’s Vyvgart. In the immunology space, regulatory applications have been filed for icotrokinra, a once-daily oral targeted peptide for plaque psoriasis that could cannibalize injectable biologics by offering superior convenience.³⁹ Management asserts that 10 of its new products or pipeline candidates possess peak sales potential exceeding $5 billion each.³⁹

In MedTech, the growth narrative relies on electrophysiology and structural heart interventions. The rollout of the VARIPULSE pulsed field ablation (PFA) system is critical. PFA is revolutionizing the treatment of atrial fibrillation by using non-thermal energy to ablate heart tissue, minimizing damage to surrounding structures like the esophagus.²⁶ However, Johnson & Johnson is arriving late to this market, fighting an uphill battle against Boston Scientific’s dominant Farapulse system and Medtronic’s Affera platform.²⁶ The integration of Shockwave’s intravascular lithotripsy technology provides a more secure growth vector, as it faces zero direct competition in cracking calcified arterial lesions.²⁸

Geographic Mix and Market Expansion

Growth is heavily skewed toward the United States, which commands disproportionate pricing power relative to international markets with single-payer systems. For the full year 2024, the United States accounted for $50.3 billion of total revenue (growing at 8.3%), while international markets generated $38.5 billion (contracting by 0.5% on a reported basis, though growing 2.9% operationally).⁴¹

The international drag is primarily sourced from the Asia-Pacific region, specifically China. The expansion of the VBP program across provinces has severely depressed MedTech realizations, effectively neutralizing the volume gains driven by an aging Chinese demographic.³⁶ Consequently, Johnson & Johnson’s growth remains fundamentally reliant on the willingness of U.S. commercial payers and Medicare to absorb premium pricing for novel therapies.

4. Capital Allocation Track Record

Management’s capital allocation is the link between business value and shareholder value. If management consistently allocates capital poorly, the intrinsic value of the business will degrade regardless of its competitive advantages. A critical assessment of Johnson & Johnson’s deployment of capital over the past decade reveals a mixed record, characterized by immense scale, exceptional R&D productivity, but highly questionable discipline regarding acquisition premiums.

Mergers & Acquisitions: A History of Overpayment?

Johnson & Johnson relies heavily on inorganic growth, sourcing approximately 50% of its product pipeline externally.⁴² This strategy is necessary to plug the massive revenue gaps created by patent cliffs, but it often requires paying exorbitant control premiums that destroy value on a strictly ROIC basis.

1. Actelion (2017 – $30 Billion): The acquisition of the Swiss biotechnology firm Actelion was executed to build a pulmonary arterial hypertension (PAH) franchise.⁴³ The deal brought Opsumit and Uptravi into the portfolio. While these drugs have performed reasonably well—generating approximately $2.18 billion and $1.81 billion respectively in 2024 ⁴¹—the $30 billion price tag represented a massive multiple of roughly 30 times estimated forward earnings at the time.⁴⁴ Furthermore, the composition patents for Opsumit are expiring, subjecting the franchise to imminent generic pressure by 2026.²³ Evaluating this acquisition on a strict ROIC basis over its lifecycle suggests that while it provided necessary revenue to mask underlying organic stagnation, it likely destroyed economic value relative to the cost of capital due to the excessive acquisition premium.
2. Momenta Pharmaceuticals (2020 – $6.5 Billion): Acquired to bolster the immunology portfolio, specifically to gain access to nipocalimab.⁴² If nipocalimab achieves its $5 billion peak sales estimate ³⁹, this acquisition will be viewed as highly accretive, demonstrating a more disciplined valuation approach than the Actelion deal.
3. Abiomed (2022 – $16.6 Billion): This acquisition established J&J as a leader in heart recovery (Impella pumps).⁴⁵ To date, this transaction appears highly successful operationally. Abiomed has consistently posted double-digit growth, serving as the foundational pillar for the MedTech division’s pivot toward higher-growth cardiovascular markets.⁴⁶
4. Shockwave Medical (2024 – $13.1 Billion): Acquired for $335 per share, Shockwave brought intravascular lithotripsy (IVL) technology to J&J.²⁷ While the technology is undisputed in its clinical utility, the financial reality is that J&J paid a massive premium for a company generating approximately $700 million in annual sales—an astounding 18.7x EV/Sales multiple.⁴⁸ Management conceded that the financing costs of this transaction would dilute adjusted EPS by $0.10 in 2024 and $0.17 in 2025.²⁷ This highlights a recurring theme: J&J uses its pristine balance sheet to buy growth, regardless of the immediate dilutive impact on return on invested capital.
5. Intra-Cellular Therapies (2025/2026 – ~$14.7 Billion): This recent acquisition secures Caplyta to bolster the Neuroscience portfolio.⁴⁷ Again, the strategy is clear—buying de-risked, commercial-stage assets to support the ambitious 2026 revenue guidance.

Internal Reinvestment: R&D Productivity

Internal R&D is the lifeblood of the Innovative Medicine segment. Johnson & Johnson consistently allocates roughly 15% to 22% of its revenue to R&D, equating to $14.6 billion to $15.1 billion annually in recent years.⁴² While the absolute dollar amount trails Merck’s massive R&D expenditure ($17.9 billion in 2024, largely preparing for the Keytruda cliff) ⁵², J&J’s R&D productivity is highly commendable.

The company successfully launched 15 major MedTech products and secured 27 Innovative Medicine approvals in major markets in 2024 alone.⁹ The successful internal development of the bispecific antibody portfolio in oncology (Tecvayli, Talvey) demonstrates that internal R&D remains a highly effective engine for value creation. Industry data suggests the internal rate of return (IRR) for late-stage biopharma pipelines has recovered to roughly 5.9% by 2024, driven by higher peak sales estimates for novel mechanisms of action despite average development costs exceeding $2.2 billion per asset.⁵⁴ J&J’s internal pipeline likely generates higher IRRs than its M&A activities, which are burdened by exorbitant goodwill premiums.

Shareholder Returns and Balance Sheet Management

Johnson & Johnson is a Dividend King, having increased its dividend for 63 consecutive years.⁵¹ In 2025, the company raised the quarterly dividend by 4.8% to $1.30 per share, yielding approximately 2.3% to 3.4% depending on market volatility.⁵⁵ The payout ratio remains highly manageable at approximately 46%, indicating ample room for future increases even amidst temporary earnings volatility.⁵¹

Share repurchases are utilized, but they appear more formulaic than opportunistic. The company spent approximately $1.9 billion on buybacks in Q4 2025, primarily to offset stock-based compensation dilution rather than to aggressively shrink the float at undervalued prices.⁶

The balance sheet remains robust, though slightly more leveraged than in its AAA-rated past due to the string of mega-acquisitions. By late 2025, the company held approximately $19.7 billion in cash and equivalents against $39.4 billion in long-term debt, maintaining a conservative debt-to-equity ratio of 0.48.⁶ This financial flexibility is a distinct competitive advantage, allowing J&J to execute $10B+ acquisitions without threatening its solvency or credit rating.

5. Recent Developments & Structural Headwinds

A critical analysis of Johnson & Johnson cannot ignore the severe, non-operational risks that threaten to decouple the stock’s valuation from its underlying business fundamentals.

The Talc Litigation: An Existential, Unquantifiable Risk

The most significant red flag surrounding Johnson & Johnson is the sprawling, decades-long talcum powder litigation. As of February 2026, the company faces over 67,622 lawsuits consolidated in a federal multidistrict litigation (MDL).⁵⁷ Plaintiffs allege that the company’s legacy talc-based baby powder was contaminated with asbestos, a known carcinogen, causing ovarian cancer and mesothelioma.⁵⁸

The financial and reputational damage is mounting exponentially. In December 2025, a Baltimore jury awarded a staggering $1.5 billion to a single plaintiff who developed mesothelioma.⁵⁷ This followed a $40 million verdict in California and a $65.5 million verdict in Minnesota earlier in the year.⁵⁷ In early 2026, a Philadelphia jury awarded an additional $250,000 in an ovarian cancer case.⁵⁷

Management’s legal strategy to ring-fence this liability has suffered catastrophic failures. The company attempted the controversial “Texas Two-Step” bankruptcy maneuver three times, creating a subsidiary (Red River Talc) to absorb the liabilities and declare Chapter 11 bankruptcy. In March 2025, a federal judge dismissed the third bankruptcy attempt, effectively killing the company’s proposed $8.2 billion global settlement framework.⁶¹ Consequently, J&J is forced to litigate these tens of thousands of cases individually in the traditional tort system.⁶²

Compounding the legal peril, in January 2026, U.S. District Judge Freda Wolfson (acting as a special master) issued a critical Daubert ruling allowing plaintiffs’ expert witnesses to testify that epidemiological evidence shows a statistically significant association between genital talc use and ovarian cancer.⁶⁰ This ruling destroys J&J’s primary defense—that the science does not support causation—and clears the path for thousands of cases to proceed to jury trials. While J&J maintains the products are safe and intends to appeal, the litigation represents a massive, unquantifiable liability that fundamentally impairs the predictability of future cash flows.

Portfolio Optimization: The Kenvue and Orthopedics Spin-offs

Under the leadership of CEO Joaquin Duato (appointed in 2022), management is actively attempting to reshape the corporate narrative from a slow-growth, defensive conglomerate to a high-growth, high-margin innovator.²³

The 2023 spin-off of the Consumer Health business (Kenvue) was the first step, shedding low-margin, slow-growth retail brands.⁶⁵ The natural continuation of this strategy is the recently announced plan to spin off the underperforming Orthopaedics division (DePuy Synthes) by mid-2027.²⁶ Generating $9.26 billion in revenue but growing at a stagnant 1.1%, Orthopaedics severely dilutes the MedTech segment’s overall performance metrics.²⁶ While spinning off the unit will mathematically improve the remaining company’s organic growth rate and margin profile, investors must view this critically: it represents an admission of defeat in a market where J&J has comprehensively lost the innovation battle to rivals.²⁹ Financial engineering cannot mask fundamental competitive deterioration.

6. Valuation Assessment

Determining the fair value of Johnson & Johnson requires balancing its exceptional free cash flow generation and robust pipeline against the severe litigation overhang and looming patent cliffs.

Current Valuation Metrics and Peer Comparison

As of early 2026, Johnson & Johnson trades at a forward Price-to-Earnings (P/E) multiple of approximately 18.4x to 21.8x, depending on the exact forward earnings estimates utilized ($11.43-$11.63 guidance).³⁶ On an Enterprise Value to EBITDA (EV/EBITDA) basis, the stock trades at roughly 14.9x to 17.2x.⁶⁸ The Free Cash Flow (FCF) yield sits tightly between 3.4% and 4.9%.⁷⁰

When evaluating these metrics against historical averages, the stock appears fully valued to slightly extended. The 5-year mean forward P/E is approximately 15.6x, indicating that the current multiple has expanded significantly in response to the aggressive 2026 revenue guidance and momentum in the oncology portfolio.²⁵

Compared to its peers, J&J occupies a middle ground that reflects its diversified nature.

• Pharma Peers: It trades at a premium to pure-play value pharmaceuticals facing immediate, catastrophic patent cliffs (e.g., Pfizer trading at ~8x-13x forward P/E). It trades largely in line with Merck (which is facing the massive Keytruda cliff in 2028) and AbbVie (which successfully navigated the Humira cliff and is growing its immunology replacements).¹⁶
• MedTech Peers: J&J trades at a discount to high-growth, pure-play medical device companies. Stryker and Boston Scientific command EV/EBITDA multiples routinely exceeding 20x, while Medtronic trades at a more modest valuation due to its own growth struggles.¹¹

Sum-of-the-Parts (SOTP) Considerations

Analyzing J&J through a Sum-of-the-Parts framework highlights the distinct valuation profiles of its two divisions.

1. Innovative Medicine (Pharma): As a standalone entity generating ~$60 billion in revenue, this business would likely trade at a mid-teens P/E multiple (14x-16x). The valuation is heavily discounted by the market to account for the Stelara erosion, the impending Xarelto IRA price cuts, and the inherent binary risks of biotech clinical trials.
2. MedTech: The MedTech division, particularly post-Orthopaedics spin-off, commands a higher premium. J&J’s cardiovascular business (Abiomed/Shockwave) is growing at nearly 16%.²⁶ This franchise deserves a structural premium (18x-22x EV/EBITDA) compared to the pharmaceutical segment due to longer product lifecycles, lower regulatory binary risk, and the high switching costs inherent in capital equipment and surgeon workflow friction.

By housing both businesses under one roof, the conglomerate structure theoretically depresses the MedTech valuation multiple, acting as an anchor, while providing vital cash flow stability to fund the high-risk Pharmaceutical R&D engine.

Cash Conversion and Earnings Quality

A critical check on valuation is earnings quality, measured by the cash conversion ratio. For the full year 2025, J&J reported Net Income of $26.8 billion and Free Cash Flow of approximately $19.7 billion to $20.4 billion.⁹ This represents a cash conversion ratio (FCF/Net Income) of roughly 73% to 76%. While generally acceptable, a ratio consistently below 100% indicates that reported earnings are somewhat inflated by non-cash items and the aggressive capitalization of R&D assets via acquisitions. It is a cautionary signal that the “quality” of the $11.03 reported EPS is slightly less robust than the headline figure suggests, urging analysts to rely more heavily on Free Cash Flow yields rather than P/E ratios when assessing intrinsic value.

7. Red Flags & Critical Questions

Beyond the glaring, existential issue of the talc litigation, several critical questions demand rigorous scrutiny:

1. M&A Value Destruction: Is management incinerating shareholder value through undisciplined capital allocation? The exorbitant premiums paid for Actelion ($30B) and Shockwave ($13.1B) suggest a management team prioritizing top-line revenue replacement over ROIC.²⁷ If the internal pipeline fails to deliver organically, will J&J continue to execute highly dilutive mega-deals to mask underlying growth decay?
2. The OTTAVA Gamble: Can Johnson & Johnson truly disrupt the surgical robotics market? Intuitive Surgical possesses an insurmountable data advantage (over 15 million procedures) and a deeply entrenched installed base of over 9,200 da Vinci systems.¹¹ The assumption that OTTAVA can seamlessly capture market share ignores the profound workflow friction and switching costs that protect incumbents. If OTTAVA fails to gain traction post-FDA clearance, a massive, multi-year R&D investment will ultimately be written off.
3. Regulatory Squeeze and the PBM Threat: The IRA represents a paradigm shift. With Xarelto and Stelara subjected to government price controls, the historical pharmaceutical model of annually raising list prices on mature drugs to drive EPS is dead.¹⁸ Concurrently, PBMs are weaponizing their formulary control to extract higher rebates, while disruptors like Amazon Pharmacy threaten to expose the artificially inflated list pricing model.³² Has the market fully priced in the margin compression that will inevitably result from these dual forces?
4. Hidden Reputational Risks: While talc dominates the headlines, J&J has a history of regulatory skirmishes, including a $70 million settlement in 2011 for Foreign Corrupt Practices Act (FCPA) violations involving bribery in Europe, and billions paid in settlements over the opioid crisis, defective DePuy hip implants, and Ethicon pelvic mesh.⁷⁵ The sheer scale of the enterprise virtually guarantees ongoing legal and regulatory friction.

8. Conclusion

To answer the central thesis: Is Johnson & Johnson a competitively advantaged business with sufficient growth prospects and strong capital allocation to warrant investment at current valuations, or is it a mature, ex-growth company trading on legacy reputation?

The empirical evidence dictates a nuanced, highly cautious conclusion. Johnson & Johnson unequivocally possesses a sustainable economic moat, evidenced by its durable ~68% gross margins, workflow friction in MedTech, and a Return on Invested Capital (14-16%) that comfortably exceeds its cost of capital. The underlying business units—particularly the oncology franchise (Darzalex, Carvykti) and the cardiovascular MedTech division (Abiomed, Shockwave)—are executing at an elite level and demonstrating clear global market leadership. Management’s 2026 guidance projecting $100 billion+ in revenue proves the company is not an ex-growth legacy trap; its pipeline is vibrant and its technological capabilities remain formidable.

However, the stock is highly unattractive for a fundamentally driven, capital-preservation-focused portfolio at the current valuation of ~19x forward earnings. The business is fundamentally besieged by risks that cannot be accurately modeled or quantified. The $300 billion pharmaceutical industry patent cliff is actively eroding the company’s highest-margin asset (Stelara). Management’s capital allocation track record is defined by paying egregious premiums for M&A to artificially plug these revenue gaps, systematically diluting near-term returns on capital.

Most critically, the 67,000+ talc lawsuits represent an existential liability. With the complete failure of the bankruptcy ring-fencing strategy and the recent Daubert ruling allowing plaintiff experts into the courtroom, the company is exposed to unlimited, multi-billion dollar jury verdicts in the traditional tort system.

At current prices, the equity offers zero margin of safety. Investors are being asked to pay a premium multiple for a company facing structural regulatory pricing pressure, imminent generic competition across multiple blockbuster franchises, and the largest mass tort liability in corporate history. The risk-adjusted return profile simply does not compensate for the extreme left-tail outcomes inherent in the ongoing talc litigation.

Frequently Asked Questions

General Questions

What thoughtful questions have other investors asked about this company? During recent earnings calls, institutional investors and analysts have focused heavily on the trajectory of the Stelara biosimilar erosion curve and how the company plans to offset this major patent cliff. They have also probed management on the integration and return on invested capital for recent mega-acquisitions like Shockwave Medical and Intra-Cellular Therapies. Other common questions center on the timeline and competitive viability of the OTTAVA robotic surgical system against incumbent Intuitive Surgical, the margin impact of the Medicare Part D redesign, and how management plans to navigate foreign headwinds like China’s Volume-Based Procurement (VBP) program and escalating international tariffs.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or cyclical low? Earnings are currently at a high point, driven by strong operational execution rather than macroeconomic cycles. In 2025, J&J reported a 90.6% year-over-year increase in net earnings to $26.8 billion, generating $11.03 in EPS. The company expects continued growth, guiding for adjusted EPS of $11.43 to $11.63 in 2026. Healthcare is largely non-cyclical, meaning these highs are structural rather than tied to business cycles.

Are earnings driven primarily by the external environment or internal company actions?

Earnings are primarily driven by internal execution—specifically R&D pipeline success, successful integration of M&A (like Abiomed and Shockwave), and commercialization strategies. However, the external environment acts as a massive headwind. External factors suppressing earnings include patent expirations (Stelara), Medicare pricing negotiations under the IRA, pharmacy benefit manager (PBM) rebate pressures, and foreign tariffs that are expected to negatively impact MedTech profits by roughly $400 million to $500 million in 2026.

How stable are revenues? Revenues are highly stable and predictable, characterized by consistent low-to-mid single-digit growth. Worldwide sales grew 6.0% to $94.2 billion in 2025, and guidance projects $100.0 billion to $101.0 billion for 2026. The diversified model across various pharmaceutical indications and medical devices smooths out volatility.

Outlook for the company’s products and services? The outlook is aggressive but faces hurdles. Management projects a 5-7% operational sales CAGR from 2025-2030 for Innovative Medicine, expecting over 10 assets to reach peak year sales of $5 billion or more (including Darzalex, Carvykti, and Tremfya). In MedTech, the cardiovascular segment is growing rapidly (nearly 16% in 2025). However, this growth must outpace the rapid decline of Stelara and the impending 2026 generic competition for Simponi, Xarelto, and Opsumit.

How big will this market be? Is it growing? Shrinking? Domestic or international? The global healthcare market is expanding rapidly due to aging demographics and rising chronic disease prevalence. J&J is highly global, though growth is currently skewed domestically. In 2024, U.S. sales were $50.3 billion (growing 8.3%), while international sales were $38.5 billion (contracting slightly on a reported basis due to currency and China VBP headwinds, but growing 2.9% operationally).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Significantly more competitive. The pharmaceutical industry is facing a “$300 billion patent cliff” between 2025 and 2030, ushering in fierce biosimilar and generic competition. Simultaneously, the MedTech segment faces intense rivalry from highly specialized competitors like Stryker (in orthopedics) and Boston Scientific (in cardiovascular).

How profitable is this business? What is the return on capital invested? Return on equity? The business is exceptionally profitable. J&J maintains durable gross margins around 67% to 69%. Net profit margin was 20.8% in Q4 2025. Return on Invested Capital (ROIC) was robust at 15.96% for the trailing twelve months ending late 2025, and Return on Equity (ROE) stood at 31.69%.

How profitable is this industry? Are there a lot of competitors? What are the barriers to entry? The pharmaceutical and MedTech industries are highly profitable but dominated by a few massive, entrenched players (e.g., Merck, Pfizer, AbbVie, Medtronic). Barriers to entry are immense. Developing a single late-stage pharmaceutical asset costs an average of $2.23 billion. Furthermore, stringent FDA/EMA regulatory processes and the necessity of navigating complex payer formularies block new entrants.

Can this business be easily understood? The overarching concept—selling medicines and surgical tools—is simple. However, the unit economics are highly complex. Understanding the business requires analyzing clinical trial data, deciphering the opaque PBM rebate system, modeling patent exclusivity timelines, and assessing global regulatory pricing frameworks.

Can this company be undermined by foreign, low-cost labor? No. J&J’s moat is built on patented intellectual property and clinical efficacy, not manufacturing arbitrage. However, foreign government policies do undermine them. China’s Volume-Based Procurement (VBP) forces severe price cuts on medical devices, acting as a structural headwind to international growth.

Do brands matter? With the spin-off of the Kenvue consumer health unit, traditional “brand” value is negligible. In pharma, doctors prescribe based on clinical data and insurance formularies, not brand loyalty. In MedTech, “brand” acts more as a proxy for surgeon familiarity; hospitals stick with J&J devices because of the extensive time surgeons spend training on their specific systems.

What is the nature of competition? Competition is based on clinical superiority (e.g., launching a “best-in-class” drug that outperforms the current standard of care), securing patent exclusivity, and successfully negotiating with PBMs for favorable insurance coverage.

What are the customers switching costs? Switching costs are bifurcated. In MedTech, switching costs are substantial due to “workflow friction.” Surgeons spend hundreds of hours mastering specific robotic or mapping platforms, making hospitals reluctant to switch vendors due to retraining costs and clinical risks. In pharma, switching costs are high for patients stabilized on chronic therapies, but these costs vanish overnight when patents expire and PBMs mandate substitution to cheaper biosimilars.

Financial Condition & Balance Sheet

Does the company have assets that are not fully recognized in the balance sheet? Yes. Like all innovative healthcare companies, J&J’s most valuable assets—its internally developed intellectual property (patents), its pipeline of pre-approval drugs, and the vast trove of clinical data it has accumulated over decades—are largely unrecognized on the balance sheet at their true economic value.

What off-balance sheet liabilities does the company have? Aside from standard operating lease obligations and purchase commitments, J&J’s most critical “off-balance sheet” threat is the mass tort talcum powder litigation. With over 67,600 pending lawsuits, this represents a massive, unquantified contingent liability.

How conservative is the company’s accounting?

J&J is historically conservative, maintaining a rare AAA credit rating from S&P Global, though it was recently placed on CreditWatch Negative due to leverage incurred from the $14.6B Intra-Cellular Therapies acquisition. The company’s Beneish M-Score of -2.54 indicates a low probability of earnings manipulation.

How CapEx hungry is this business? It is moderately CapEx hungry (spending ~$4.4 billion on property and equipment in 2024) , but it is incredibly R&D hungry. The company consistently invests over $14.6 billion to $15.1 billion annually in research and development to sustain its pipeline.

Capital Allocation & Management

How much free cash flow does the business generate? How does management use this free cash flow? What is their philosophy? J&J generated approximately $19.7 billion to $20.4 billion in free cash flow in 2025. Management’s capital allocation philosophy prioritizes R&D investment first, followed by paying a competitive and annually increasing dividend, executing value-creating M&A, and conducting strategic share repurchases.

Has the company made any significant acquisitions recently?

Yes, management has been highly aggressive. They recently announced the acquisition of Intra-Cellular Therapies for $14.6 billion (early 2025), acquired Shockwave Medical for $13.1 billion in mid-2024, and bought Abiomed for $16.6 billion in late 2022.

Is the company buying back shares? Yes. J&J spent approximately $1.9 billion on share repurchases in Q4 2025, primarily returning capital to shareholders and reducing the outstanding share count.

What is the compensation policy of directors and management?

The executive compensation program emphasizes a “pay for performance” structure. Compensation is significantly weighted toward long-term equity awards to align executive financial interests with the long-term performance of the business and shareholder returns.

What are the motivations of management? Management is motivated to successfully navigate the company through its current patent cliff and transition it into a higher-growth enterprise. CEO Joaquin Duato has set an explicit goal to make J&J the #1 oncology company in the world by 2030, targeting $50 billion in oncology sales alone.

Valuation & Market Data

Is the stock an ADR? MLP? K-1? No, Johnson & Johnson (JNJ) is standard common stock listed on the New York Stock Exchange.

Dividend Policy? J&J is a “Dividend King.” In 2025, the company raised its dividend for the 63rd consecutive year to $1.30 per quarter ($5.20 annualized). The payout ratio is very safe at approximately 46%.

Is net income diverging from cash from operations? There is a slight divergence. For every $1 of reported net income, J&J generates roughly $0.92 in operating cash flow. This cash conversion ratio (below 1.0x) indicates that some of the reported earnings rely on non-cash accounting items, which is common given the heavy amortization associated with their recent string of mega-acquisitions.

Risks & Downside

What factors would cause the stock to decline? The stock is vulnerable to an acceleration in Stelara market share loss to biosimilars, clinical trial failures in the oncology or immunology pipelines, heavier-than-expected margin compression from government price controls (IRA), or the failure of their OTTAVA surgical robot to gain FDA clearance and market traction against Intuitive Surgical.

What is the risk of a catastrophic loss? / Chance of a total loss?

A complete total loss of capital (bankruptcy) is virtually zero due to J&J’s $19.7 billion cash pile, immense free cash flow, and AAA credit rating. However, the talc litigation represents an unquantifiable, catastrophic tail risk. With courts dismissing J&J’s “Texas Two-Step” bankruptcy shielding maneuver, the company is exposed to the traditional tort system where single-plaintiff verdicts have recently hit $1.5 billion.

Recent News & Events

Has the business environment changed recently? Yes. The U.S. regulatory environment has shifted aggressively with the implementation of the Inflation Reduction Act (IRA), which enforces mandatory price cuts on key drugs like Xarelto. Additionally, escalating global trade tensions are actively hurting the company, with management expecting $400 million to $500 million in tariff-related costs in 2026, primarily impacting the MedTech supply chain.

Has the company recently changed accounting policies?

As of the latest filings through 2025, the company reported that there were no new material accounting standards adopted or issued that impacted their financials.

Recent changes in the business, new markets, new production facilities, what’s changed recently? Strategically, J&J is actively shedding slower-growth divisions. Having already spun off its consumer health segment (Kenvue) in 2023, management recently announced plans to spin off its Orthopaedics business (DePuy Synthes) by mid-2027 to focus purely on high-growth cardiovascular, vision, and surgical robotics. Operationally, they are investing over $55 billion into U.S. infrastructure by 2029, including a new $2 billion biologics facility in North Carolina and a $1 billion cell therapy manufacturing site in Pennsylvania.

Works cited

1. JNJ (Johnson & Johnson) ROIC % – GuruFocus, accessed February 23, 2026, https://www.gurufocus.com/term/roic/JNJ
2. Johnson & Johnson (JNJ) ROIC – Current & Historical Data (Feb 2026), accessed February 23, 2026, https://www.financecharts.com/stocks/JNJ/value/roic
3. Johnson & Johnson (JNJ) Return on Equity (ROE), accessed February 23, 2026, https://www.financecharts.com/stocks/JNJ/growth/roe
4. Johnson & Johnson Gross Margin 2012-2025 | JNJ – Macrotrends, accessed February 23, 2026, https://www.macrotrends.net/stocks/charts/JNJ/johnson-johnson/gross-margin
5. JNJ Profitability Analysis – Johnson & Johnson – Alpha Spread, accessed February 23, 2026, https://www.alphaspread.com/security/nyse/jnj/profitability
6. JNJ Financials: Income Statement, Balance Sheet & Cash Flow, accessed February 23, 2026, https://www.stocktitan.net/financials/JNJ/
7. Switching costs in medical education – PMC – NIH, accessed February 23, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3783829/
8. Alcon Investment Analysis: Competitive Advantage, https://drive.google.com/open?id=1aXzoEhGLyOI7PzFLoGov1MPQGEQep3G96Vuyoo0LK3E
9. Johnson & Johnson reports Q4 and Full-Year 2025 results, accessed February 23, 2026, https://www.investor.jnj.com/investor-news/news-details/2026/Johnson–Johnson-reports-Q4-and-Full-Year-2025-results/default.aspx
10. Johnson & Johnson Clears the Patent Cliff as 2026 Guidance, accessed February 23, 2026, https://www.investing.com/analysis/johnson–johnson-clears-the-patent-cliff-as-2026-guidance-resets-the-narrative-200673620
11. What is Competitive Landscape of Intuitive Surgical Company?, accessed February 23, 2026, https://portersfiveforce.com/blogs/competitors/intuitive
12. Surgical Robots: The Best Amazing Rivals – Liv Hospital, accessed February 23, 2026, https://int.livhospital.com/surgical-robots-the-best-amazing-rivals/
13. Top 8 Robotic Surgery Companies in the United States, accessed February 23, 2026, https://idataresearch.com/top-robotic-surgery-companies-in-the-united-states/
14. The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels, accessed February 23, 2026, https://www.drugchannels.net/2025/10/the-stelara-biosimilar-price-war-how.html
15. Biosimilar expansion: New competition for Stelara in 2025, accessed February 23, 2026, https://business.caremark.com/insights/2024/new-biosimilar-competition-stelara.html
16. $300 Billion in Pharma Revenue Loses Patent Protection by 2030, accessed February 23, 2026, https://deepceutix.com/insights/patent-cliff-reformulation
17. How Big Pharma is navigating a $300 billion patent cliff | PharmaVoice, accessed February 23, 2026, https://www.pharmavoice.com/news/big-pharma-navigating-patent-cliff-300-billion-jnj-merck-abbvie/810915/
18. Kill the Patent Cliff: How to Turn a $400 Billion Revenue Loss into a, accessed February 23, 2026, https://www.drugpatentwatch.com/blog/kill-the-patent-cliff-how-to-turn-a-400-billion-revenue-loss-into-a-competitive-edge/
19. J&J signs Stelara biosimilar settlement deal with Formycon and, accessed February 23, 2026, https://www.pharmaceutical-technology.com/news/jj-signs-stelara-biosimilar-settlement-deal-formycon-fresenius/
20. J&J Posts Innovative Medicine Growth in 2025 Amid Stelara Patent, accessed February 23, 2026, https://www.nasdaq.com/articles/jj-posts-innovative-medicine-growth-2025-amid-stelara-patent-loss
21. Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings, accessed February 23, 2026, https://www.zacks.com/stock/news/2873014/why-is-johnson-johnson-jnj-up-13-since-last-earnings-report
22. Johnson & Johnson reports Q4 and Full-Year 2025 results, accessed February 23, 2026, https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results
23. Johnson & Johnson 2026 Outlook: Patent Cliffs, Pipeline … – SyneticX, accessed February 23, 2026, https://www.syneticx.com/blog/jnj.html
24. The Drug Patent Cliff Portfolio: A Strategic Guide to Identifying and, accessed February 23, 2026, https://www.drugpatentwatch.com/blog/the-drug-patent-cliff-portfolio-a-strategic-guide-to-identifying-and-investing-in-companies-facing-major-expiries/
25. J&J’s MedTech Shows Strong Growth in 2025: Will 2026 be Better?, accessed February 23, 2026, https://www.nasdaq.com/articles/jjs-medtech-shows-strong-growth-2025-will-2026-be-better
26. J&J’s cardiovascular business boosts medtech growth in 2025, accessed February 23, 2026, https://www.medtechdive.com/news/jnj-q4-full-year-earnings-cardiovascular/810121/
27. Johnson & Johnson To Acquire Shockwave Medical, accessed February 23, 2026, https://shockwavemedical.com/news/johnson-johnson-to-acquire-shockwave-medical/
28. JnJ’s Shockwave buyout jolts the medtech sector, defying GLP-1, accessed February 23, 2026, https://www.atonra.ch/research/jnjs-shockwave-buyout-jolts-the-medtech-sector-defying-glp-1-concerns
29. Johnson & Johnson Orthopedics: Inside the Strategic Spin-Out, accessed February 23, 2026, https://www.lifesciencemarketresearch.com/insights/johnson-johnson-orthopedics-inside-the-strategic-spin-out
30. Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings, accessed February 23, 2026, https://finviz.com/news/317521/why-is-johnson-johnson-jnj-up-13-since-last-earnings-report
31. Roche AG Investment Analysis, https://drive.google.com/open?id=1dwauYtzWQagMQDX0liZltJyS416g7lFOtkr0sVVIZv4
32. A Case Study of Johnson & Johnson’s Prescription Drug Pricing, accessed February 23, 2026, https://smithrx.com/blog/the-cost-of-discount-focused-pbms-johnson-johnson
33. Pharma Pulse: Amazon Pharmacy Sells Oral Wegovy, J&J’s Billion, accessed February 23, 2026, https://www.pharmaceuticalcommerce.com/view/pharma-pulse-amazon-weight-loss-pivot
34. CVS vs. Amazon, and Healthcare Consumerism – Hospitalogy, accessed February 23, 2026, https://hospitalogy.com/articles/2025-06-12/cvs-vs-amazon-and-healthcare-consumerism/
35. Johnson & Johnson chief figures Amazon could shake up pharma’s, accessed February 23, 2026, https://www.fiercepharma.com/pharma/amazon-could-shake-up-distribution-reimbursement-for-pharma-j-j-ceo
36. J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both, accessed February 23, 2026, https://www.nasdaq.com/articles/jj-targets-100b-sales-2026-growth-accelerates-both-units
37. Is J&J’s MedTech Segment Set for Another Quarter of Growth?, accessed February 23, 2026, https://www.nasdaq.com/articles/jjs-medtech-segment-set-another-quarter-growth
38. Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings, accessed February 23, 2026, https://www.nasdaq.com/articles/why-johnson-johnson-jnj-13-last-earnings-report
39. JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your, accessed February 23, 2026, https://www.nasdaq.com/articles/jnj-vs-mrk-which-blue-chip-pharma-stock-should-be-your-portfolio
40. The top medtech trends in 2024, accessed February 23, 2026, https://www.medtechdive.com/news/medtech-trends-outlook-2024/706019/
41. Please find detailed revenue data by segment from Johnson, accessed February 23, 2026, https://xbrl.us/wp-content/uploads/2025/08/APPENDIX-JJ-Results-of-Search.pdf
42. Equity Research Report Johnson & Johnson – RUN, accessed February 23, 2026, https://run.unl.pt/bitstream/10362/181869/1/FALL25_57984_Justin_Jacob.pdf
43. Johnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out, accessed February 23, 2026, https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-actelion
44. Johnson & Johnson Pays $30 Billion for Actelion, Will Spin Off R&D, accessed February 23, 2026, https://www.biospace.com/it-s-finally-happening-johnson-and-johnson-pays-30-billion-for-actelion-will-spin-off-r-and-d-unit-with-1-billion-cash
45. J&J Acquires Abiomed for $16.6 Billion – Knobbe Martens, accessed February 23, 2026, https://www.knobbe.com/blog/jj-acquires-abiomed-166-billion/
46. Presentation title goes here, accessed February 23, 2026, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/Final-JNJ-Earnings-Presentation-Q1-2025-Webcastv2.pdf
47. Investment analysis of Johnson & Johnson, accessed February 23, 2026, https://trade.tfos.com/ideas/details/17511
48. Johnson & Johnson + Shockwave Medical, accessed February 23, 2026, https://s203.q4cdn.com/636242992/files/doc_events/2024/Apr/FINAL_JNJ-SWAV-Investor-Presentation.pdf
49. Healthcare EBITDA Multiples: 2026 Dashboard – FOCUS, accessed February 23, 2026, https://focusbankers.com/healthcare-ebitda-multiples/
50. Big Pharma’s R&D ROI: Merck, Pfizer, J&J, AbbVie strategies, accessed February 23, 2026, https://www.drugdiscoverytrends.com/are-big-pharma-giants-getting-the-right-roi-on-their-rd-investments-a-visual-exploration/
51. Johnson & Johnson: A Steady Investment with Strong Returns, accessed February 23, 2026, https://intellectia.ai/news/stock/johnson–johnson-a-steady-investment-with-strong-returns
52. Top 10 pharma R&D budgets in 2024 – Fierce Biotech, accessed February 23, 2026, https://www.fiercebiotech.com/special-reports/top-10-pharma-rd-budgets-2024
53. Johnson & Johnson 2024 Annual Report, accessed February 23, 2026, https://s203.q4cdn.com/636242992/files/doc_downloads/Annual_meeting/2025/Johnson-Johnson-2024-Annual-Report.pdf
54. Measuring the return from pharmaceutical innovation 2025 | Deloitte …, accessed February 23, 2026, https://www.deloitte.com/ch/en/Industries/life-sciences-health-care/research/measuring-return-from-pharmaceutical-innovation.html
55. Announces 63 rd Consecutive Year of Dividend Increase; Raises, accessed February 23, 2026, https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-63rd-consecutive-year-of-dividend-increase-raises-quarterly-dividend-by-4-8
56. Johnson & Johnson: Robust Dividend Growth Bolsters Investment, accessed February 23, 2026, https://www.kavout.com/market-lens/johnson-johnson-robust-dividend-growth-bolsters-investment-appeal
57. Talcum Powder Lawsuit Updates & Latest News | February 2026, accessed February 23, 2026, https://www.sokolovelaw.com/product-liability/talcum-powder/lawsuit-updates/
58. Talcum Powder Lawsuit: (February 2026) Ovarian Cancer Claims, accessed February 23, 2026, https://www.drugwatch.com/talcum-powder/lawsuits/
59. Talcum Powder Lawsuit | 2026 Update & Settlements, accessed February 23, 2026, https://www.mesotheliomahope.com/legal/talcum-powder-lawsuit/
60. Talc Powder Ovarian Cancer Lawsuit – Lawsuit Information Center, accessed February 23, 2026, https://www.lawsuit-information-center.com/2-billion-verdict-in-missouri-motivates-jj-to-settle-talcum-powder-lawsuits.html
61. Talcum Powder Settlement | $8.2Billion Johnson & Johnson Offer, accessed February 23, 2026, https://www.consumernotice.org/legal/talcum-powder-settlements/
62. REFINITIV STREETEVENTS – EDITED TRANSCRIPT – JNJ.N – Q1 …, accessed February 23, 2026, https://s203.q4cdn.com/636242992/files/doc_financials/2025/q1/JNJ_N-Transcript-2025-04-15T12_30.pdf
63. Johnson & Johnson Talc Ovarian Cancer Lawsuits to Proceed in, accessed February 23, 2026, https://www.rheingoldlaw.com/product-liability-lawsuit/johnson-johnson-talc-ovarian-cancer-lawsuits-to-proceed-in-federal-mdl-litigation-talc-litigation-update-february-2026/
64. Big Pharma CEOs set sights on massive growth in years to come, accessed February 23, 2026, https://www.pharmavoice.com/news/big-pharma-earnings-jnj-pfizer-merck-upshot/811439/
65. jnj stock value — Johnson & Johnson – Bitget, accessed February 23, 2026, https://www.bitget.com/wiki/jnj-stock-value
66. Johnson & Johnson Stock: 2026 Outlook After 50% Gains – TIKR.com, accessed February 23, 2026, https://www.tikr.com/blog/johnson-johnson-stock-2026-outlook-after-50-gains
67. Johnson & Johnson (NYSE:JNJ) P/E Ratio – Investing.com NG, accessed February 23, 2026, https://ng.investing.com/pro/NYSE:JNJ/explorer/pe_ltm
68. JNJ (Johnson & Johnson) EV-to-EBITDA – GuruFocus, accessed February 23, 2026, https://www.gurufocus.com/term/enterprise-value-to-ebitda/JNJ
69. Johnson & Johnson – Public Comps and Valuation Multiples, accessed February 23, 2026, https://multiples.vc/public-comps/johnson-and-johnson-valuation-multiples
70. Unlevered Free Cash Flow Yield For Johnson & Johnson (JNJ), accessed February 23, 2026, https://finbox.com/NYSE:JNJ/explorer/fcf_unlev_yield_ltm
71. Johnson & Johnson (JNJ) FCF Yield – Current & Historical Data (Feb, accessed February 23, 2026, https://www.financecharts.com/stocks/JNJ/value/fcf-yield
72. JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment, accessed February 23, 2026, https://www.tradingview.com/news/zacks:e8ba0394a094b:0-jnj-vs-pfe-which-blue-chip-drug-stock-is-the-better-investment-now/
73. JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth, accessed February 23, 2026, https://www.nasdaq.com/articles/jnj-vs-abbv-which-pharma-powerhouse-has-better-growth-prospects
74. Johnson & Johnson Free Cash Flow 2012-2025 | JNJ – Macrotrends, accessed February 23, 2026, https://www.macrotrends.net/stocks/charts/JNJ/johnson-johnson/free-cash-flow
75. Johnson & Johnson – Products, Recalls, Lawsuits & Scandals, accessed February 23, 2026, https://www.drugwatch.com/manufacturers/johnson-and-johnson/
76. Johnson & Johnson – Enforcement and Litigation – SEC.gov, accessed February 23, 2026, https://www.sec.gov/enforcement-litigation/litigation-releases/lr-21922
77. johnson-and-johnson | Violation Tracker – Good Jobs First, accessed February 23, 2026, https://violationtracker.goodjobsfirst.org/parent/johnson-and-johnson